Acute intoxications with "legal highs" and recreational drugs - Challenges for toxicologists;Ostre zatrucia "dopalaczami" i "substancjami rozrywkowymi" - Wyzwania dla toksykologów

Problems of Forensic Sciences

Volumn 80, Issue , 2009, Pages 450-458

  Klimaszyk, Dorota ^a,b   Nawrocka, Katarzyna ^a  

^a F Raszeja Hospital   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Acute intoxication; Dopalacze (legal highs); Psychoactive substances; Recreational drugs

Indexed keywords

ILLICIT DRUG; RECREATIONAL DRUG;

ARTICLE; DRUG DEPENDENCE; DRUG USE; INTERVIEW; INTOXICATION; KNOWLEDGE; POLAND;

EID: 77952005783     PISSN: 12307483     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Babu K., Boyer E. W., Hernon C. [et al.], Emerging drugs of abuse, Clinical Pediatric Emergency Medicine 2005, 6, 81-84.
2. Babu K., McCurdy C. R., Boyer E. W., Opioid receptors and legal highs: Salvia divinorum and Kratom, Clinical Toxicology 2008, 46, 146-152.
3. Bankson M. G., Cunningham K. A., 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions, The Journal of Pharmacology and Experimental Therapeutics 2001, 297, 846-852.
4. Dart R. C., Medical toxicology, Williams and Wilkins, Lippincot 2004.
5. 2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro, The Journal of Neuroscience 2008, 28, 2933-2940. (Pubitemid 351398883)
6. Hersh E. V., Pinto A., Moore P. A., Adverse drug interactions involving common prescription and over-the-counter analgesic agents, Clinical Therapeutics 2007, 29, 2477-2497.
7. Koob G. F., Bloom F. E., Cellular and molecular mechanisms of drug dependence, Science 1988, 242, 715-723.
8. Łukasik-Głȩbocka M., Dekstrometorfan i benzydamina - nowe substancje odurzaja̧ce, Serwis Informacyjny - Narkomania 2008, 41, 16-19.
9. Machoy-Mokrzyńska A., Borowiak K., Białecka M., Neuronalne i molekularne mechanizmy powstawania uzależnień, Annales Academiae Medicae Stetinensis 2007, 53, 9-12.
10. Monitoring biologiczny narażenia na czynniki chemiczne w środowisku pracy, Jakubowski M. [red.], Instytut Medycyny Pracy, Łódź 1997.
11. Murray S., Brewerton T., Abuse of over the counter dextromethorphan by teenagers, Southern Medical Journal 1993, 86, 1151-1153.
12. Mycyk M. B., Tudor B. C., DiMaano J. Q., ED visits and hospitalizations are increasing among young adults abusing oral narcotics, Clinical Toxicology 2005, 43, 668.
13. Nicholson K. L., Balster R. L., GHB: a new and novel drug of abuse, Drug and Alcohol Dependence 2001, 63, 1-22.
14. Olds J., Milner P. M., Positive reinforcement produced by electric stimulation of septal area and other regions of rat brain, Journal of Comparative & Physiological Psychology 1954, 47, 419-427.
15. Partilla J. S., Dempsey A. G., Nagpal A. S. [et al.], Interaction of amphetamines and related compounds at the vesicular monoamine transporter, Journal of Pharmacology and Experimental Therapeutics 2006, 319, 237-246.
16. Richardson W. H., Slone C. M., Michels J. E., Herbal drugs of abuse: An emerging problem, Emergency Medicine Clinics of North America 2007, 25, 435-457.
17. Schechter M. D., Use of TFMPP stimulus properties as a model of 5-HT1B receptor activation, Pharmacology Biochemistry & Behavior 1988, 31, 53-57.
18. Schwartz R. H., Adolescent abuse of dextromethorphan, Clinical Pediatrics 2005, 44, 565-568.
19. Sierosławski J., Bukowska B., Substancje psychoaktywne - postawy i zachowania. Raport z badań ankietowych przeprowadzonych w Łodzi w 2004 r., Warszawa 2004.
20. Spanagel R., Weiss F., The dopamine hypothesis of reward: past and current status, Trends in Neurosciences 1999, 22, 521-527. (Pubitemid 29481853)
21. Vetulani J., Uzależnienia lekowe: mechanizmy neurobiologiczne i podstawy farmakoterapii, Alkoholizm i Narkomania 2001, 14, 13-58.
22. Wachowiak R., Ocena toksykologiczna metod diagnostycznych stosowanych w zatruciach środkami psychoaktywnymi, Przegla̧d Lekarski 2001, 58, 215-219.
23. Wilkins C., Sweetsur P., Differences in harm from legal BZP/TFMPP party pills between North Island and South Island users in New Zealand: A case of effective industry self-regulation?, International Journal of Drug Policy 2009, [in press, doi:10.1016/j.drugpo.2009.02.005].
24. Wood D. M., Warren-Gash C., Ashraf T. [et al.], Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD), QJM 2008, 101, 23-29.
25. Woynarowska B., Mazur J., Używanie substancji psychoaktywnych i inne zachowania ryzykowne u młodzieży w wieku 11-15 lat w Polsce w 2002 roku, Alkoholizm i Narkomania 2003, 6, 155-171.
26. Yan F., Roth B. L., Salvinorin A., A novel and highly selective kappa-opioid receptor agonist, Life Sciences 2004, 75, 2615-2619. (Pubitemid 39215054)
27. Zacny J. P., Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users, Drug and Alcohol Dependence 2005, 80, 273-278.
28. Ziaee V., Hamed E. A., Hoshmand A. [et al.], Side effects of dextromethorphan abuse, a case series, Addictive Behaviours 2005, 20, 1607-1613.